Биохимия,
Journal Year:
2023,
Volume and Issue:
88(7), P. 1069 - 1084
Published: Dec. 15, 2023
The
mechanisms
of
carcinogenesis
are
extremely
complex.
Many
players
determine
the
scenario
malignant
cell
transformation,
tumor
growth
and
metastasis.
In
recent
decades,
more
attention
has
been
paid
to
role
symbiotic
human
microbiota
in
regulation
metabolism
functioning
immune
system
host
organism.
Such
a
symbiosis
macroorganism
its
microorganisms
was
combined
into
concept
holoorganism.
process
coevolution
participants
holoorganism,
ways
their
interaction
were
formed,
metabolites
acquired
special
-
signaling
molecules
main
regulators
molecular
interactions
Being
involved
pathways
host,
bacterial
turned
out
be
obligatory
both
physiological
pathological
processes,
including
growth.
At
same
time,
effects
often
have
multidirectional
character,
manifested
impact
on
functions
cells
metabolic
activity
composition
microbiome.
This
review
discusses
some
microbiotic
induction
prevention
transformation
organism,
as
well
influence
effectiveness
anticancer
therapy.
We
tried
draw
reader’s
components
orchestra
microbial
initiation
progression
Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(21), P. 6578 - 6578
Published: Nov. 1, 2024
Colorectal
cancer
(CRC)
constitutes
a
significant
global
health
challenge,
with
recent
studies
underscoring
the
pivotal
role
of
gut
microbiome
in
its
pathogenesis
and
progression.
Fecal
microbiota
transplantation
(FMT)
has
emerged
as
compelling
therapeutic
approach,
offering
potential
to
modulate
microbial
composition
optimize
treatment
outcomes.
Research
suggests
that
specific
bacterial
strains
are
closely
linked
CRC,
influencing
both
clinical
management
interventions.
Moreover,
microbiome's
impact
on
immunotherapy
responsiveness
heralds
new
avenues
for
personalized
medicine.
Despite
promise
FMT,
safety
concerns,
particularly
immunocompromised
individuals,
remain
critical
issue.
Clinical
outcomes
vary
widely,
influenced
by
genetic
predispositions
methodologies
employed.
Additionally,
rigorous
donor
selection
screening
protocols
paramount
minimize
risks
maximize
efficacy.
The
current
body
literature
advocates
establishment
standardized
further
trials
substantiate
FMT's
CRC
management.
As
our
understanding
deepens,
FMT
is
poised
become
cornerstone
treatment,
imperative
continued
research
validation.
Gut Microbes,
Journal Year:
2025,
Volume and Issue:
17(1)
Published: Jan. 18, 2025
The
integration
of
fecal
microbiota
transplantation
(FMT)
with
immune
checkpoint
inhibitors
(ICIs)
presents
a
promising
approach
for
enhancing
cancer
treatment
efficacy
and
overcoming
therapeutic
resistance.
This
review
critically
examines
the
controversial
effects
FMT
on
ICIs
outcomes
elucidates
underlying
mechanisms.
We
investigate
how
modulates
gut
composition,
microbial
metabolite
profiles,
tumor
microenvironment,
thereby
influencing
effectiveness.
Key
factors
efficacy,
including
donor
selection
criteria,
recipient
characteristics,
administration
protocols,
are
comprehensively
discussed.
delineates
strategies
optimizing
formulations
systematically
monitoring
post-transplant
microbiome
dynamics.
Through
comprehensive
synthesis
evidence
from
clinical
trials
preclinical
studies,
we
elucidate
potential
benefits
challenges
combining
across
diverse
types.
While
some
studies
report
improved
outcomes,
others
indicate
no
benefit
or
adverse
effects,
emphasizing
complexity
host-microbiome
interactions
in
immunotherapy.
outline
critical
research
directions,
encompassing
need
large-scale,
multi-center
randomized
controlled
trials,
in-depth
ecology
multi-omics
approaches
artificial
intelligence.
Regulatory
ethical
addressed,
underscoring
imperative
standardized
protocols
rigorous
long-term
safety
assessments.
seeks
to
guide
future
endeavors
applications
FMT-ICIs
combination
therapy,
improve
patient
while
ensuring
both
efficacy.
As
this
rapidly
evolving
field
advances,
maintaining
judicious
balance
between
openness
innovation
cautious
scrutiny
is
crucial
realizing
full
modulation
Inflammation,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 7, 2025
Asthma
is
a
prevalent
chronic
inflammatory
disorder
of
the
respiratory
tract
that
not
only
manifests
with
symptoms
but
also
often
involves
intestinal
flora
disorders
and
gastrointestinal
dysfunction.
Recent
studies
have
confirmed
close
relationship
between
gut
lungs,
known
as
"gut-lung
axis"
theory.
Fecal
microbiota
transplantation
(FMT),
method
for
restoring
normal
flora,
has
shown
promise
in
treating
common
diseases.
The
theory
suggests
FMT
may
significant
therapeutic
potential
asthma.
In
this
study,
we
established
an
Ovalbumin
(OVA)-induced
rat
model
asthma
to
investigate
protective
effect
on
airway
inflammation
restoration
short-chain
fatty
acids
(SCFAs),
aiming
explore
its
underlying
mechanism.
Rats
Control
group
underwent
fecal
treatment
via
gavage
(Control-FMT,
C-FMT
group),
while
rats
after
induction
(Asthma-FMT,
A-FMT
group).
Following
two-week
period
continuous
intragastric
administration,
various
measurements
were
conducted
assess
pulmonary
function,
peripheral
blood
neutrophil,
lymphocyte,
eosinophil
content,
lung
tissue
pathology,
collagen
fiber
deposition
lungs.
Additionally,
neutrophil
content
bronchoalveolar
lavage
fluid
(BALF),
expression
levels
Interleukin-4
(IL-4),
IL-5,
IL-13,
IL-17,
IL-33,
leukotrienes
(LT),
thymic
stromal
lymphopoietin
(TSLP),
prostaglandin
D2
(PGD2)
protein
mRNA
tissue,
SCFAs
stool
evaluated.
group,
function
significantly
improved,
cell
BALF
decreased,
pathology
factors
IL-4,
LT,
TSLP,
PGD2
such
acetate
(C2),
propionate
(C3),
butyrate
(C4),
isobutyric
acid
(I-C4),
valeric
(C5),
isovaleric
(I-C5)
increased.
However,
indexes
did
show
recovery,
was
inferior
group.
induced
rats,
improved
response
asthmatic
models
corrected
their
disorders.
Encouraging
recovery
play
role,
beneficial
bacteria
present
feces
improve
by
promoting
remodeling
flora.
This
experiment
provides
further
scientific
evidence
supporting
The Oncologist,
Journal Year:
2024,
Volume and Issue:
29(10), P. 824 - 832
Published: June 26, 2024
Colorectal
cancer
(CRC)
is
a
major
cause
of
cancer-related
deaths
globally.
While
treatment
advancements
have
improved
survival
rates,
primarily
through
targeted
therapies
based
on
KRAS,
NRAS,
and
BRAF
mutations,
personalized
strategies
for
CRC
remain
limited.
Immunotherapy,
mainly
immune
checkpoint
blockade,
has
shown
efficacy
in
various
cancers
but
effective
only
small
subset
patients
with
deficient
mismatch
repair
(dMMR)
proteins
or
high
microsatellite
instability
(MSI).
Recent
research
challenged
the
notion
that
immunologically
inert,
revealing
subsets
immunogenicity
diverse
lymphocytic
infiltration.
Identifying
precise
biomarkers
beyond
dMMR
MSI
crucial
to
expanding
immunotherapy
benefits.
Hence,
exploration
extended
biomarker
sources,
such
as
tumor
microenvironment,
genomic
markers,
gut
microbiota.
studies
introduced
novel
classification
system,
consensus
molecular
subtypes,
aids
identifying
an
immunogenic
profile.
These
findings
underscore
necessity
moving
single
toward
comprehensive
understanding
immunological
landscape
CRC,
facilitating
development
more
effective,
therapies.
Heliyon,
Journal Year:
2024,
Volume and Issue:
10(15), P. e35336 - e35336
Published: July 27, 2024
Gastrointestinal
(GI)
cancers
represent
a
significant
global
health
challenge,
driving
relentless
efforts
to
identify
innovative
diagnostic
and
therapeutic
approaches.
Recent
strides
in
microbiome
research
have
unveiled
previously
underestimated
dimension
of
cancer
progression
that
revolves
around
the
intricate
metabolic
interplay
between
GI
host's
gut
microbiota.
This
review
aims
provide
comprehensive
overview
these
emerging
interactions
their
potential
catalyze
paradigm
shift
precision
diagnosis
breakthroughs
cancers.
The
article
underscores
groundbreaking
impact
on
oncology
by
delving
into
symbiotic
connection
host
metabolism
It
offers
valuable
insights
tailoring
treatment
strategies
individual
patients,
thus
moving
beyond
traditional
one-size-fits-all
approach.
also
sheds
light
novel
methodologies
could
transform
early
detection
cancers,
potentially
leading
more
favorable
patient
outcomes.
In
conclusion,
exploring
microbiota
showcases
promising
frontier
ongoing
battle
against
formidable
diseases.
By
comprehending
harnessing
microbiome's
influence,
future
innovation
for
appears
optimistic,
opening
doors
tailored
treatments
enhanced
precision.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(16), P. 2644 - 2644
Published: Aug. 10, 2024
Breast
cancer
(BC)
is
one
of
the
most
common
cancers
worldwide
and
a
leading
cause
cancer-related
deaths
among
women.
The
escalating
incidence
BC
underscores
necessity
multi-level
treatment.
complex
heterogeneous
disease
involving
many
genetic,
lifestyle,
environmental
factors.
Growing
evidence
suggests
that
nutrition
intervention
an
evolving
effective
prevention
treatment
strategy
for
BC.
In
addition,
human
microbiota,
particularly
gut
now
widely
recognized
as
significant
player
contributing
to
health
or
status.
It
also
associated
with
risk
development
This
review
will
focus
on
in
BC,
including
dietary
patterns,
bioactive
compounds,
nutrients
affect
therapeutic
responses
both
animal
studies.
Additionally,
this
paper
examines
impacts
these
interventions
modulating
composition
functionality
microbiome,
highlighting
microbiome-mediated
mechanisms
combination
factors
microbes
discussed.
Insights
from
emphasize
comprehensive
management
focuses
nutrition–microbiome
axis.
Clinical and Experimental Medicine,
Journal Year:
2024,
Volume and Issue:
25(1)
Published: Nov. 28, 2024
Abstract
The
term
"microbiome"
refers
to
the
collection
of
bacterial
species
that
reside
in
human
body's
tissues.
Sometimes,
it
is
used
refer
all
microbial
entities
(bacteria,
viruses,
fungi,
and
others)
which
colonize
body.
It
now
generally
acknowledged
microbiome
plays
a
critical
role
host's
physiological
processes
general
well-being.
Changes
structure
and/or
function
(dysbiosis)
are
linked
development
many
diseases
including
cancer.
claim
because
their
negatively
charged
membrane,
cancer
cells
more
vulnerable
some
bacteria
than
normal
how
link
between
these
evolved
has
been
refuted.
Furthermore,
relationship
evident
emerging
field
immunotherapy.
In
this
narrative
review,
we
detailed
correlation
presence/absence
specific
development,
diagnosis,
prognosis,
treatment
types
colorectal,
lung,
breast,
prostate
addition,
discussed
mechanisms
microbiome–cancer
interactions
genotoxin
production,
free
radicals,
modification
signaling
pathways
host
cells,
immune
modulation,
modulation
drug
metabolism
by
microbiome.
Future
directions
clinical
application
early
detection,
emphasizing
on
fecal
transplantation,
probiotics,
prebiotics,
biomarkers
were
also
considered.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(6), P. 2040 - 2040
Published: March 17, 2025
Oncologists
increasingly
recognize
the
microbiome
as
an
important
facilitator
of
health
well
a
contributor
to
disease,
including,
specifically,
cancer.
Our
knowledge
etiologies,
mechanisms,
and
modulation
states
that
ameliorate
or
promote
cancer
continues
evolve.
The
progressive
refinement
adoption
“omic”
technologies
(genomics,
transcriptomics,
proteomics,
metabolomics)
utilization
advanced
computational
methods
accelerate
this
evolution.
academic
center
network,
with
its
immediate
access
extensive,
multidisciplinary
expertise
scientific
resources,
has
potential
catalyze
research.
Here,
we
review
our
current
understanding
role
gut
in
prevention,
predisposition,
response
therapy.
We
underscore
promise
operationalizing
network
uncover
structure
function
microbiome;
highlight
unique
microbiome-related
expert
resources
available
at
City
Hope
Comprehensive
Cancer
Center
example
team
science
achieve
novel
clinical
discovery.
